The role of desmin alterations in mechanical electrical feedback in heart failure

This study provides a potential therapeutic target for VA in HF.
Source: Life Sciences - Category: Biology Source Type: research

Related Links:

This study adds to the body of evidence in describing incidence and type of cardiac events experienced by an allogeneic and autologous HSCT population at one institution from 2012-2017. Sixty-five patients (9.8%) experienced cardiac events, including atrial arrhythmia (N = 39), acute heart failure (N = 9), acute coronary syndrome (N = 7), new onset hypertension (N = 9), with a few instances of bradycardia, ventricular arrhythmia, pericardial effusion, and pericarditis. Our multivariable regression analysis identified age (older), creatinine (higher) and history of coronary artery disease to significantly correlate with ris...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Authors: Du Z, Xu W, Chen X, Xu D, Li Y, Zhang H, Gao L PMID: 31937077 [PubMed - as supplied by publisher]
Source: Minerva Cardioangiologica - Category: Cardiology Tags: Minerva Cardioangiol Source Type: research
Authors: Correa A, Rochlani Y, Aronow WS Abstract Introduction: Heart failure (HF) affects over 6 million Americans and is the most common cause of hospital readmissions in the United States. Cardiac arrhythmias are common comorbidities seen in patients with HF and are associated with an increase in morbidity and mortality. Pharmacotherapeutic agents along with device and ablation therapies are the mainstays of treatment for cardiac arrhythmias in HF.Areas covered: An extensive literature review of articles and clinical trials on PUBMED on the topic of pharmacotherapy for cardiac arrhythmias in heart failure was co...
Source: Expert Opinion on Pharmacotherapy - Category: Drugs & Pharmacology Tags: Expert Opin Pharmacother Source Type: research
Studies have revealed a robust and independent correlation between chronic kidney disease (CKD) and cardiovascular (CV) events, including death, heart failure, and myocardial infarction. Recent clinical trials extend this range of adverse CV events, including malignant ventricular arrhythmias and sudden cardiac death (SCD). Moreover, other studies point out that cardiac structural and electrophysiological changes are a common occurrence in this population. These processes are likely contributors to the heightened hazard of arrhythmias in CKD population and may be useful indicators to detect patients who are at a higher SCD...
Source: Frontiers in Physiology - Category: Physiology Source Type: research
Conclusion: In this study, the significant difference between the electrocardiographic data of deceased and surviving dilated cardiomyopathy patients suggests that electrocardiographic data should be evaluated in detail in order to determine the low and high risk of mortality in patients with dilated cardiomyopathy.What is Known:•Previous studies on the relationship between limited electrocardiography data of adult patients diagnosed with DCM and mortality have been determinedWhat is New:•ECG data has not been investigated in such detail in child DCM patients,as in our study.
Source: European Journal of Pediatrics - Category: Pediatrics Source Type: research
We report the case of biventricular hypertrabeculation in a 54 ‐year‐old woman who presented with congestive heart failure de novo associated with arrhythmia in a low‐income setting. We also discussed the therapeutic challenges. AbstractVentricular noncompaction or hypertrabeculation is rare and unclassified cardiomyopathy that mostly affects the left ventricle. We report the case of biventricular hypertrabeculation in a 54 ‐year‐old woman who presented with congestive heart failure de novo associated with arrhythmia in a low‐income setting. We also discussed the therapeutic challenges.
Source: Clinical Case Reports - Category: General Medicine Authors: Tags: CASE REPORT Source Type: research
SUMMARY Hyperkalemia is a frequent finding in patients with chronic kidney disease (CKD). This increase in serum potassium levels is associated with decreased renal ion excretion, as well as the use of medications to reduce the progression of CKD or to control associated diseases such as diabetes mellitus and heart failure. Hyperkalemia increases the risk of cardiac arrhythmia episodes and sudden death. Thus, the control of potassium elevation is essential for reducing the mortality rate in this population. Initially, the management of hyperkalemia includes orientation of low potassium diets and monitoring of patients' adh...
Source: Revista da Associacao Medica Brasileira - Category: General Medicine Source Type: research
Advances in care during the earliest years of life have transformed the epidemiology of congenital heart disease (CHD) with expansion of the adult CHD (ACHD) population becoming larger than the paediatric one [1]. However, these patients are not cured and can develop cardiovascular complications in mid and late adult life, especially in those with complex lesions. Heart failure is one of the most common complications with a life prevalence of at least 30%, continues to increase as patients age, and represents the leading cause of death in ACHD.
Source: International Journal of Cardiology - Category: Cardiology Authors: Tags: Editorial Source Type: research
This article presents a review of the current knowledge on HF in rTOF patients, including incidence and prevalence, the most common mechanisms of heart failure, i.e., valvular pathologies, shunt lesions, left atrial hypertension, primary left heart and right heart failure, arrhythmias, and coronary artery disease. In addition, we will review information regarding extracardiac complications, risk factors for the development of heart failure, clinical impact and prognosis, and assessment possibilities, particularly of the right ventricle, as well as management strategies. We explore potential future concepts that may stimula...
Source: Heart Failure Reviews - Category: Cardiology Source Type: research
Abbott Laboratories has won a nod from FDA for a new alternative surgical technique for the HeartMate 3 Left Ventricular Assist Device (LVAD). This technique will not only allow more advanced heart failure patients the opportunity to avoid open-heart surgery, but it will help advance the firm's position in the LVAD market.  Dublin-based Medtronic won the same designation for the HVAD in 2018. Abbott said the HeartMate 3 heart pump can now be implanted through an incision in the chest wall. The new FDA nod for HeartMate 3 is based on two studies – the ELEVATE study: a multi-center, voluntary, o...
Source: MDDI - Category: Medical Devices Authors: Tags: Cardiovascular Regulatory and Compliance Source Type: news
More News: Arrhythmia | Biology | Cancer & Oncology | Cardiology | Heart | Heart Failure | Study